Alembic Pharma is planning a capex of about Rs 400 crore in FY26. (Image Source: Freepik) Show Quick Read Summary is AI Generated. Newsroom Reviewed

Alembic Pharmaceuticals is targeting to raise its Ebitda margins to 18-20% over the next couple of years, according to the company’s Managing Director, Pranav Amin. The company is hopeful of improving its margins due to enhanced capacity and production ramp-up in the second half of the current financial year.

“We're doing pretty okay on capacities. Some are completely full, while others are ramping up. The other plants will ramp up as well in the second half. And that is why you will see a margin improvement, not just the second half, but moving forward from the current 17% Ebitda margins. I believe that over the next couple of years, w

See Full Page